Teva Pharmaceutical (Germany) Probability of Future Stock Price Finishing Under 5.31
| TEV Stock | EUR 21.20 0.20 0.95% |
Teva |
Teva Pharmaceutical Target Price Odds to finish below 5.31
The tendency of Teva Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to € 5.31 or more in 90 days |
| 21.20 | 90 days | 5.31 | near 1 |
Based on a normal probability distribution, the odds of Teva Pharmaceutical to drop to € 5.31 or more in 90 days from now is near 1 (This Teva Pharmaceutical Industries probability density function shows the probability of Teva Stock to fall within a particular range of prices over 90 days) . Probability of Teva Pharmaceutical price to stay between € 5.31 and its current price of €21.2 at the end of the 90-day period is close to 99 .
Assuming the 90 days horizon Teva Pharmaceutical has a beta of 0.44. This usually implies as returns on the market go up, Teva Pharmaceutical average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Teva Pharmaceutical Industries will be expected to be much smaller as well. Additionally Teva Pharmaceutical Industries has an alpha of 0.4994, implying that it can generate a 0.5 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Teva Pharmaceutical Price Density |
| Price |
Predictive Modules for Teva Pharmaceutical
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Teva Pharmaceutical. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Teva Pharmaceutical Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Teva Pharmaceutical is not an exception. The market had few large corrections towards the Teva Pharmaceutical's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Teva Pharmaceutical Industries, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Teva Pharmaceutical within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.50 | |
β | Beta against Dow Jones | 0.44 | |
σ | Overall volatility | 1.17 | |
Ir | Information ratio | 0.13 |
Teva Pharmaceutical Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Teva Pharmaceutical for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Teva Pharmaceutical can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Teva Pharmaceutical appears to be risky and price may revert if volatility continues | |
| Teva Pharmaceutical has high likelihood to experience some financial distress in the next 2 years | |
| Teva Pharmaceutical has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Teva Pharmaceutical Industries has accumulated 19.1 B in total debt with debt to equity ratio (D/E) of 184.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Teva Pharmaceutical has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Teva Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Teva Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Teva Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Teva to invest in growth at high rates of return. When we think about Teva Pharmaceutical's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 14.93 B. Net Loss for the year was (2.35 B) with profit before overhead, payroll, taxes, and interest of 6.97 B. |
Teva Pharmaceutical Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Teva Stock often depends not only on the future outlook of the current and potential Teva Pharmaceutical's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Teva Pharmaceutical's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.1 B |
Teva Pharmaceutical Technical Analysis
Teva Pharmaceutical's future price can be derived by breaking down and analyzing its technical indicators over time. Teva Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Teva Pharmaceutical Industries. In general, you should focus on analyzing Teva Stock price patterns and their correlations with different microeconomic environments and drivers.
Teva Pharmaceutical Predictive Forecast Models
Teva Pharmaceutical's time-series forecasting models is one of many Teva Pharmaceutical's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Teva Pharmaceutical's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Teva Pharmaceutical
Checking the ongoing alerts about Teva Pharmaceutical for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Teva Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Teva Pharmaceutical appears to be risky and price may revert if volatility continues | |
| Teva Pharmaceutical has high likelihood to experience some financial distress in the next 2 years | |
| Teva Pharmaceutical has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Teva Pharmaceutical Industries has accumulated 19.1 B in total debt with debt to equity ratio (D/E) of 184.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Teva Pharmaceutical has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Teva Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Teva Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Teva Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Teva to invest in growth at high rates of return. When we think about Teva Pharmaceutical's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 14.93 B. Net Loss for the year was (2.35 B) with profit before overhead, payroll, taxes, and interest of 6.97 B. |
Other Information on Investing in Teva Stock
Teva Pharmaceutical financial ratios help investors to determine whether Teva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Teva with respect to the benefits of owning Teva Pharmaceutical security.